Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by inthnoon Aug 17, 2023 12:52pm
256 Views
Post# 35593177

onc

onc
Until it is writing and signed, nothing is for sure especially with onc and no disputing this.
1)First we need to get the definitive agreements signed
2) Then will be partner or go it alone- that will affect the sp for sure
3) Esmo could bring some excitement but sp will not hold as it did not hold for aware1, Bracelet or Panc as we are now down approx. 40% from just a month ago
4)It has been stated by onc that the trial will not start until 2024 and readout apprx. 17 months after the trial start so in 2025 as stated by Andrew in the quarterly cc.
5) Surprises can happen along the way and that is all we can hope for but it would appear that there is not a lot of support for the sp even with all the good news or we would not be where we are right now.
6) As we all know a partnership or BO can happen anytime but this has been stated for years so until we get that announcement we are where we are and all the posts stating otherwise will not make a difference other than to give hope for a brighter future with the company.
7) will the agreements be signed and announced within the 90 days is yet to be seen and we shall know soon enough
8) onc does have a bright future but they need to get moving in the changing landscape and get a phase 3 trial up and running to prove and put pressure on all concerned even if it is going it alone but they better get it right if that is the case and not mess it up like the Bracelet with the wrong CI and patient removals with the high temps that everyone already knew about.
9) Time to step up , get it done and move forward and sooner than later
<< Previous
Bullboard Posts
Next >>